McLean, VA, November 28, 2017 –(– Perthera, Inc., the leading Therapeutics Intelligence Company™, has announced its partnership with ZERO, the leading nonprofit prostate cancer advocacy group in the USA, to form and launch the nationwide Decode Your Prostate Cancer program aimed to provide each prostate cancer patient with therapeutic treatment options precisely matched to their individual cancer.

“We are extremely pleased to work with the team at ZERO. Perthera’s mission is to provide cancer patients with precisely matched therapeutic treatment options specific to their individual cancer through our Perthera Report™. In joining forces with Zero, together we will bring a significant and effective new tool for doctors, hospitals and patients across the US to fight prostate cancer.” – Neal G. Koller, President & CEO, Perthera, Inc.

In a combined effort, Perthera and ZERO have created the Decode Your Prostate Cancer program, giving ZERO-affiliated patients and their doctors and hospitals access to the Perthera Report which provides precisely matched therapeutic options ranked for the highest probability of best outcome. The Perthera Report will provide them with the best information for fighting their specific prostate cancer.

"One of the most significant recent breakthroughs in the fight against cancer is pinpointing the patient's tumor characteristics. The Perthera Report accomplishes this and more by providing ranked therapeutic options that have been reviewed by Perthera’s expert and scientific tumor board. With this critical data; we're able to put men battling prostate cancer on the best individualized treatment pathway; getting them back to life with their families." – Jamie Bearse, President & CEO, ZERO – The End of Prostate Cancer.

One in eight American men will have prostate cancer during his lifetime. Prostate cancer is the third leading cause of cancer death among American men and is the most commonly diagnosed. Learn more about the Decode Your Prostate Cancer program at

About Perthera, Inc.:
Perthera is the leading Therapeutic Intelligence Company advancing precision medicine through its Perthera Report, which precisely matches cancer patients with multiple therapeutic options ranked by highest probability of best outcome.

About ZERO – The End of Prostate Cancer:
ZERO is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. ZERO is a 501(c)(3) philanthropic organization, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 84 cents of every dollar to research and programs. For more information, visit

Contact Information:
Perthera, Inc.
Phil Robertson
Contact via Email

Read the full story here:

Press Release Distributed by